 Teacher Yang Yanping's team from Longhua Hospital, Shanghai University of Traditional Chinese Medicine Recently 《Materials & Design》（IF7.6） The article "Photodynamic-therapy and chemotherapy of TPBC-PEG nanoplatform encapsulated triptolide synergistically inhibit primary osteosarcoma growth and pulmonary metastasis by activating HIPPO signaling" was published on Qihengxing's flagship product FS-P1005 (StarLighter Reverse Transcription Super Mix (with gDNA Removal)) I am fortunate to be able to participate in this and contribute to this research! Professor Yang Yanping's team has developed a novel nanoplatform (TP-TPBC-PEG) coated with triptolide (TP), which is pH-responsive and near-infrared light-activated. This nanoplatform combines photodynamic therapy (PDT) and chemotherapy, providing a promising new approach for treating osteosarcoma and preventing lung metastasis by activating the HIPPO signaling pathway (Figure 1). Figure 1. Effect and molecular mechanism of TP-TPBC-PEG nanomicelles in inhibiting primary osteosarcoma growth and lung metastasis. The article describes in detail the synthesis, characterization, in vitro pH responsiveness study, drug release study, cell uptake, cell activity experiment, migration and invasion experiment, RT-qPCR and Western blot analysis of TP-TPBC-PEG nanomicelles. In vitro experimental results showed that the TP-TPBC-PEG nanoplatform could reduce cell viability, colony formation, migration and invasion, and enhance the sensitivity of osteosarcoma cells to TP chemotherapy under laser irradiation. In vivo experimental results showed that in an osteosarcoma mouse model, the TP-TPBC-PEG nanoplatform, after tail vein injection, accumulated at the site of osteosarcoma and significantly inhibited osteosarcoma growth and lung metastasis under laser irradiation. Furthermore, in vivo experiments showed no organ toxicity, indicating good biosafety. Previous studies by the authors have found that the HIPPO signaling pathway is involved in the anti-osteosarcoma activity of TPBC-PEG nanomicelles under laser irradiation. This study demonstrated that the TP-TPBC-PEG nanoplatform significantly inhibited the expression of YAP and TAZ proteins, which are key effectors of the HIPPO signaling pathway. In addition, YAP/TAZ downstream transcriptional targets, such as AMOTL2, CTGF, CYR61, and ANKRD1, which are known to promote tumor growth, survival, and metastasis, were significantly downregulated after treatment. This indicates that TP-TPBC-PEG nanomicelles activate the HIPPO signaling pathway, which is the key molecular mechanism of their osteosarcoma inhibition effect (Figure 2). The article also mentioned that this study also has certain limitations, namely the use of a mouse model, which may not fully replicate the complexity of osteosarcoma in human patients. In addition, although the research data showed a significant therapeutic effect, the long-term safety and potential toxicity of repeated TP-TPBC-PEG nanomicelle treatment require further study. In summary, this study provides strong evidence for the efficacy of TP-TPBC-PEG nanomicelles in the treatment of osteosarcoma. By combining PDT and chemotherapy with HIPPO pathway activation, this nanoplatform offers a synergistic approach to address both primary tumor growth and metastatic spread. This comprehensive study, from synthesis and characterization to mechanistic insights, makes TP-TPBC-PEG nanomicelles a promising candidate for further development as a targeted therapeutic strategy for osteosarcoma. Product Express Tracer effect of tracer premix Surprise Trial Scan the QR code to request a trial pack |
